Citigroup
FTH

Citigroup’s Faeth Therapeutics FTH Stock Holding History

Citigroup’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-294
Closed -$3.14K – 6367
2025
Q4 		$3.14K Buy
+294
New +$2.84K ﹤0.01% 5368
2025
Q2 		– Sell
-6
Closed -$49 – 5893
2025
Q1 		$49 Buy
+6
New +$57 ﹤0.01% 5452
2022
Q4 		– Sell
-18
Closed -$1K – 5941
2022
Q3 		$1K Sell
18
-16
-47% -$629 ﹤0.01% 5686
2022
Q2 		$2K Sell
34
-72
-68% -$2.7K ﹤0.01% 5918
2022
Q1 		$5K Sell
106
-215
-67% -$17.1K ﹤0.01% 5836
2021
Q4 		$37K Buy
321
+201
+168% +$30K ﹤0.01% 5206
2021
Q3 		$25K Buy
120
+102
+567% +$18.6K ﹤0.01% 5137
2021
Q2 		$4K Sell
18
-7
-28% -$1.73K ﹤0.01% 5882
2021
Q1 		$7K Buy
+25
New +$8.37K ﹤0.01% 5813

Other funds holding FTH

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Citigroup's FTH Position: Q1 2026 in Review

Citigroup sold out of Faeth Therapeutics (FTH) in Q1 2026, closing a stake of 294 shares — an estimated $3.14K sold.

Citigroup first reported a position in FTH in Q1 2021 and held it in 9 quarters. The position peaked at $37K in Q4 2021. 30 funds tracked by Wall St. Rank hold FTH as of Q1 2026.

  • Citigroup reported no remaining Faeth Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 294 Faeth Therapeutics shares in Q1 2026, an estimated $3.14K.
  • Citigroup first reported a position in Faeth Therapeutics in Q1 2021 and held it in 9 quarters.
  • Citigroup's Faeth Therapeutics position peaked at $37K in Q4 2021.
  • 30 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.